Claritev Corporation (CTEV)
| Market Cap | 512.29M -29.3% |
| Revenue (ttm) | 978.76M +5.5% |
| Net Income | -286.52M |
| EPS | -17.33 |
| Shares Out | 17.05M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 126,894 |
| Open | 30.41 |
| Previous Close | 30.39 |
| Day's Range | 29.16 - 30.46 |
| 52-Week Range | 11.50 - 74.07 |
| Beta | 0.70 |
| Analysts | Buy |
| Price Target | 36.83 (+22.56%) |
| Earnings Date | Aug 7, 2026 |
About CTEV
Claritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers claims intelligence solutions, including reference-based pricing, negotiation services, surprise bill services, and Vistara; network solutions, such as primary networks, complementary networks, and network build and network management services; and payment and revenue integrity solutions comprising clinical neg... [Read more]
Financial Performance
In 2025, Claritev's revenue was $965.41 million, an increase of 3.74% compared to the previous year's $930.62 million. Losses were -$284.28 million, -82.73% less than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for CTEV stock is "Buy." The 12-month stock price target is $36.83, which is an increase of 22.56% from the latest price.
News
Sun Life U.S. and Claritev work to boost efficiency of supplemental health benefits
WELLESLEY, Mass. and MCLEAN, Va., July 16, 2026 /PRNewswire/ -- Sun Life U.S., a leading provider of employee and government benefits, and Claritev, a healthcare technology, data and insights company,...
Claritev Corporation Announces Second Quarter 2026 Earnings Conference Call
MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a healthcare technology, data and insights company focused on making healthcare more affordable, transpar...
Justice Department expands antitrust probe into Claritev, Bloomberg says
The Justice Department is expanding an antitrust investigation into Claritev (CTEV) over allegations the company helped insurers, including UnitedHealth (UNH), CVS Health’s (CVS) Aetna and Cigna (CI),...
DOJ expands Claritev antitrust investigation, Bloomberg reports
13:00 EDT DOJ expands Claritev (CTEV) antitrust investigation, Bloomberg reports
Claritev drops 13% to $25.93 following Bloomberg report
13:00 EDT Claritev (CTEV) drops 13% to $25.93 following Bloomberg report
Claritev Rises to Leader Ranking in Everest Group's 2026 Pre-Payment Integrity Solutions PEAK Matrix® Assessment
MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (NYSE: CTEV), a technology, data, and insights company focused on making healthcare more affordable and transparent, today announced it has been reco...
Claritev Corporation Announces Participation in Truist Securities Healthcare Disruptors & Digital Health Conference
MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fai...
Claritev price target lowered to $61 from $90 at Piper Sandler
Piper Sandler lowered the firm’s price target on Claritev (CTEV) to $61 from $90 and keeps an Overweight rating on the shares.
Claritev Cares and Elizabeth Dole Foundation Team Up to Help Military and Veteran Caregivers Navigate Mental Health Benefits
MCLEAN, Va. & WASHINGTON--(BUSINESS WIRE)---- $CTEV #ClaritevCares--Claritev Cares, the charitable foundation established by Claritev (NYSE: CTEV), and the Elizabeth Dole Foundation today announced a ...
Canaccord starts Claritev with a Buy amid return to growth
As previously reported, Canaccord initiated coverage of Claritev (CTEV) with a Buy rating and $32 price target As a leading provider of out-of-network pricing and payment integrity solutions, Claritev...
Claritev initiated with a Buy at Canaccord
Canaccord initiated coverage of Claritev (CTEV) with a Buy rating and $32 price target
Claritev says cooperating with DOJ, not informed of being target
Claritev (CTEV) disclosed that nn article published on Thursday, May 14, 2026 alleges that “DOJ launches criminal antitrust probe into Claritev.” In August of 2024, the company said it received…
Claritev jumps after saying DOJ has not informed company of being target
The shares are up 20%, or $2.78, to $16.65 in midday trading.
Claritev probed by DOJ’s antitrust division, Capitol Forum reports
The Justice Department’s antitrust division has launched a criminal price-fixing investigation into Claritev (CTEV), a pricing intermediary that major health insurers use to set reimbursement rates fo...
Claritev rallies after commenting on last week’s Capitol Forum report
12:29 EDT Claritev (CTEV) rallies after commenting on last week’s Capitol Forum report
Claritev discloses criminal antitrust probe by Justice Department
12:24 EDT Claritev (CTEV) discloses criminal antitrust probe by Justice Department
Claritev Transcript: Bank of America Global Healthcare Conference 2026
Management outlined a strong growth trajectory, with record Q1 bookings, robust pipeline expansion, and ambitious revenue and EBITDA targets through 2030. Strategic investments in technology and AI, along with deep client relationships, are expected to drive continued success.
Claritev price target raised to $40 from $21 at Citi
In a sector note on U.S. HealthTech & Distribution, Citi raised the firm’s price target on Claritev (CTEV) to $40 from $21 and keeps a Buy rating on the shares,…
Claritev Launches PHCS Novera to Give TPAs More Control Over Network Design Amid Rising Healthcare Costs
MCLEAN, Va.--(BUSINESS WIRE)---- $CTEV #CostContainment--As healthcare costs accelerate and employers demand more control over network strategy, Claritev Corporation (NYSE: CTEV), a healthcare technol...
Claritev Corporation Announces Participation in BofA Securities Global Health Care Conference 2026
MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fai...
Claritev Earnings Call Transcript: Q1 2026
Q1 saw revenue and EBITDA exceed expectations, driven by strong core and expansion performance, record ACV bookings, and operational efficiencies from AI. Raised revenue guidance and maintained EBITDA outlook, with continued investment in growth and deleveraging focus.
Claritev Earnings release: Q1 2026
Claritev released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Claritev Slides: Q1 2026
Claritev has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Claritev reports Q1 EPS ($4.41) vs. ($4.38) last year
Reports Q1 revenue $244.7M, consensus $238.59M. “Claritev (CTEV) kicked off 2026 the same way we closed 2025, outperforming on the top and bottom lines with focused execution in sales, operations…
Claritev narrows FY26 revenue view to $985M-$1B from $980M-$1B
FY26 revenue consensus $990.02M. Backs FY26 adjusted EBITDA view $605M-$615M and CapEx view $160M-$170M.